Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
"Today is a landmark day for the uveal melanoma community, with NICE's recommendation of the first treatment to prolong survival in HLA-A*02:01-positive adults with metastatic or unresectable uveal melanoma. Uveal melanoma is a very rare form of melanoma which requires different clinical management. The option to prescribe tebentafusp is a step change for patients and their families, and we continue to support the process so that there is reimbursement for the therapy across the UK for all eligible patients," said Susanna Daniels, CEO of Melanoma Focus.
Immunocore在英格蘭宣佈與KIMMTRAK▼達成報銷協議，以治療HLA-A*02:01陽性的不可切除或轉移性葡萄膜黑色素瘤成人。
"今天是葡萄膜黑色素瘤社區的一個里程碑日，NICE推薦了第一種治療方法，以延長HLA-A*02:01陽性成人的生存期，這些成人患有轉移性或不可切除的葡萄膜黑色素瘤。葡萄膜黑色素瘤是一種非常罕見的黑色素瘤，需採用不同的臨床管理。開處方tebentafusp的選項是對患者和他們家庭的重大改變，我們將繼續支持這一過程，以便在英國爲所有符合條件的患者提供該療法的報銷，" Melanoma Focus的首席執行官Susanna Daniels表示。